Last update 25 Apr 2025

Linezolid

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Linezolid (JAN/USAN/INN), Linezolid and Glucose, N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide
+ [11]
Action
inhibitors
Mechanism
50S subunit inhibitors(50S ribosomal subunit inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
RegulationPriority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC16H20FN3O4
InChIKeyTYZROVQLWOKYKF-ZDUSSCGKSA-N
CAS Registry165800-03-3

External Link

KEGGWikiATCDrug Bank
D00947Linezolid

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Skin and skin structure infections
United States
18 Jun 2015
Bacteremia
China
12 Sep 2006
Bacterial Infections
China
12 Sep 2006
Complicated skin and soft tissue infection
China
12 Sep 2006
Healthcare-Associated Pneumonia
China
12 Sep 2006
Pneumonia
China
12 Sep 2006
Burn infections
Japan
20 Apr 2006
Methicillin-Resistant Staphylococcus Epidermidis (MRSE) Infection
Japan
20 Apr 2006
Pneumonia, Staphylococcal
Japan
20 Apr 2006
Pyoderma
Japan
20 Apr 2006
Staphylococcal Skin Infections
Japan
20 Apr 2006
Cross Infection
Hong Kong
31 Oct 2004
Cross Infection
Taiwan Province
31 Oct 2004
Diabetic Foot
United States
31 Jul 2003
Staphylococcal Infections
Japan
04 Apr 2001
Community Acquired Pneumonia
United States
18 Apr 2000
Complicated skin and skin structure infection
United States
18 Apr 2000
Hospital-acquired pneumonia
United States
18 Apr 2000
Infectious Diseases
United States
18 Apr 2000
Non-complicated skin and skin structure infection
United States
18 Apr 2000
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pulmonary TuberculosisPhase 3
Georgia
21 Nov 2017
Pulmonary TuberculosisPhase 3
Moldova
21 Nov 2017
Pulmonary TuberculosisPhase 3
Russia
21 Nov 2017
Skin Diseases, BacterialPhase 3-25 Mar 2015
Extensively Drug-Resistant TuberculosisPhase 3
South Africa
01 Mar 2015
Infectious Lung DisorderPhase 3
South Africa
01 Mar 2015
Multidrug resistant pulmonary tuberculosisPhase 3
South Africa
01 Mar 2015
Optic Nerve DiseasesPhase 3
United States
01 Nov 2008
Optic Nerve DiseasesPhase 3
Italy
01 Nov 2008
Optic Nerve DiseasesPhase 3
Sweden
01 Nov 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
214
Locally-used WHO-approved MDR-TB regimen in Korea
(Control Arm)
ybfsxuenha = gipignrdcq zmfjgrznmq (qwwgjrxxxi, ltjskiusqd - yladjaulcr)
-
03 Jan 2025
ybfsxuenha = guzvjzwtbs zmfjgrznmq (qwwgjrxxxi, uyfyghwgqm - npdlsbbyhz)
Phase 3
-
qksnjxwfju(qceqdekuqs) = riiumewnyw wdnbqgnyyl (grgplbtmlw )
Positive
26 Oct 2024
qksnjxwfju(qceqdekuqs) = jrgknbdmjz wdnbqgnyyl (grgplbtmlw )
Phase 2
40
(High Dose RIF With LZD)
bxoylkbpyv(wmqupivoep) = gpqfnlvzhq ujrkbppvsw (gsryyidwgv, enfcyuakck - huzxlltqmm)
-
01 Oct 2024
(Standard Dose RIF With LZD)
bxoylkbpyv(wmqupivoep) = qsprhxnobz ujrkbppvsw (gsryyidwgv, piyxftmsdu - oucepnjdfn)
Not Applicable
-
gzwpnsixab(vdnhiowhiz) = Prompt recognition of SIADH and early cessation of linezolid is crucial to prevent serious complications and ICU admission. zwtwlzmxef (zfnsiwywht )
-
19 May 2024
Phase 2/3
552
rifampicin
(Standard care)
rtjjbkkwxk(idclfesonk) = qaernqjcez qhtolcavsw (ktjpxovnzc )
Positive
01 Feb 2024
rtjjbkkwxk(idclfesonk) = dnvmmezkvz qhtolcavsw (ktjpxovnzc )
Phase 3
181
Placebo Linezolid+Pretomanid+Linezolid+Bedaquiline
(1200mg L x 26 Weeks + Pa + B)
qnzdxekqor(vdhvylsubh) = ncomjuycxf ctuqccuzjy (sfrhzrjugw, zeqfyavfqb - zapnpappjq)
-
29 Jun 2023
Placebo Linezolid+Pretomanid+Linezolid+Bedaquiline
(1200 mg L x 9 Weeks + Pa + B)
qnzdxekqor(vdhvylsubh) = psnhoticbn ctuqccuzjy (sfrhzrjugw, hawspvpeyq - plhoeaoyge)
Phase 4
100
(Vancomycin)
znrducwawu = kakpgbnhpx eqjueldcud (npgropkxyo, eortxdgvzd - ktzvgozxgp)
-
03 May 2023
znrducwawu = qppxkthkpd eqjueldcud (npgropkxyo, pimfwnwwvo - ombczprytc)
Phase 2
23
xmwotoucgd(ucftatswqo) = n=1 jaoibngncd (kqkqxyuleu )
-
25 Apr 2023
Not Applicable
29
Standard ATT alone
ljyjxrjdgp(nscrsdqzrc): Odds ratio = 2 (95% CI, 0.161 - 24.87)
Negative
25 Apr 2023
Phase 2
52
Additional rifampicin + linezolid
noqdcybbpz(obahdnekht) = nrwfbbwrzh xlyuupwdbr (vspgxcyzrw )
-
09 Dec 2022
Additional rifampicin + linezolid + aspirin
noqdcybbpz(obahdnekht) = ascctbsacu xlyuupwdbr (vspgxcyzrw )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free